Developing a new cancer treatment targeting specific proteins
Official title: Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy
Funded at Medical University of South Carolina · NIH-11001442 · Data updated 2026-11-12
This study is looking at a new treatment that could help make chemotherapy work better for people with ovarian and pancreatic cancer by blocking certain proteins that help cancer cells survive.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | December 29, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $180,811 |
| NIH project number | 5R01CA276378-04 |
| Project ID | NIH-11001442 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with epithelial ovarian cancer or pancreatic ductal adenocarcinoma who have not responded well to standard treatments.
✕Less likely to help
Patients with other types of cancer or those who have not been diagnosed with epithelial ovarian cancer or pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on improving treatments for epithelial ovarian cancer and pancreatic ductal adenocarcinoma, two aggressive forms of cancer. It investigates a novel small molecule that inhibits specific proteins responsible for cancer cell survival, aiming to enhance the effectiveness of existing chemotherapy. By blocking these proteins, the treatment seeks to promote cancer cell death and overcome resistance to current therapies. The research involves preclinical testing in laboratory models to evaluate the potential of this new approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that improve survival rates for patients with difficult-to-treat cancers.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in cancer treatment, indicating that this approach could be a meaningful advancement in cancer therapy.
Where this research is happening
-
Medical University of South Carolina
Charleston, United States Active
Researchers
- Principal investigator: Hawkins, William G — Medical University of South Carolina
- Study coordinator: Hawkins, William G
Related research
Other NIH-funded projects on the same topics.
-
Il1rapl2’s role in shaping cortical wiring in autism
This project studies how a brain gene linked to autism helps form the connections in deep-layer neurons to understand why circuits develop differently in ASD.
-
Neuron-OPC Synaptic Mechanisms Shaping Myelin in Health and Disease
This project looks at how brain cells called oligodendrocyte precursor cells (OPCs) listen to neurons to shape myelin, with potential relevance for autism and related conditions.
-
Synaptic development and sleep-related brain circuits in autism
A study in mice explores how early brain circuits that help sleep become wired, hoping to understand sleep problems in autism.
-
Enteric neuron and intestinal stem cell signals shaping gut barrier
A research project from the Medical University of South Carolina explores how nerve cells in the gut talk to the lining and stem cells to defend the digestive tract, using human organoids and mouse models.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.